Showing 2781-2790 of 4110 results for "".
- Cynosure Partners with Jeisys Medical Japanhttps://practicaldermatology.com/news/cynosure-partners-with-jeisys-medical-japan/2461114/Cynosure LLC’s subsidiary Cynosure KK has entered into a distribution partnership with Jeisys Medical KK, a subsidiary of Jeisys Medical Inc. in Japan. Under the terms of the agreement, Jeisys Medical will have exclusive distribution rights for products within Cynosure&
- Dermatology Refresher Symposium for PAs and NPs Coming to San Antoniohttps://practicaldermatology.com/news/dermatology-refresher-symposium-for-pas-and-nps-coming-to-san-antonio/2461112/The 2nd Annual Dermatology Refresher Symposium (DRS) for NPs and PAs comes to Texas next month. The in-person program will be held on April 8-10, 2022 at the Grand Hyatt San Antonio River Walk in San Antonio. DRS is offering com
- PCA SKIN® Recognizes Third Annual National Peel Dayhttps://practicaldermatology.com/news/pca-skin-recognizes-third-annual-national-peel-day/2461104/PCA SKIN® wants to know #HowYouPeelin, as the company celebrates the third annual National Peel Day, Thursday, highlighting their latest peel innovation, new partnership, special promotion for accounts, and a host of social media activities.&
- Dermatologists Can Support Medical, Humanitarian Efforts in Ukrainehttps://practicaldermatology.com/news/how-to-help-ukraine/2461103/Many Americans feel hopeless as they watch images of displaced Ukrainian citizens fleeing their country due to ongoing Russian attacks. EADV President Professor Alexander Stratigos and Secretary General Professor Carmen Salavastru have issued a sta
- Study: Use of DermTech’s Melanoma Test Can Cut Costshttps://practicaldermatology.com/news/study-use-of-dermtechs-melanoma-test-can-cut-costs/2461102/New research shows that DermTech’s Pigmented Lesion Assay can reduce costs for commercial health insurance plans when it’s incorporated into the current care pathway of assessing pigmented skin lesions or moles suspicious for melanoma The
- Aquaphor Unveils New Purpose-Driven Brand Campaignhttps://practicaldermatology.com/news/aquaphor-unveils-new-purpose-driven-brand-campaign/2461099/Aquaphor is launching its first-ever brand purpose campaign, "Before & Aquaphor." Inspired by the growing field of psychodermatology, this new integrated campaign highlights the connection between our skin health and our emotional well-being.
- Successful Topline Results Seen for Hallura's New BiOLinkMatrix HA Aesthetic Fillershttps://practicaldermatology.com/news/successful-topline-results-seen-for-halluras-new-biolinkmatrix-ha-aesthetic-fillers/2461096/Hallura Ltd’s hyaluronic acid (HA) dermal fillers with its proprietary BiOLinkMatrix platform performed well for lip enhancement, nasolabial folds correction. and cheek enhancement, according to topline results. The proprietary Bi
- Cetaphil Sensitive Skin Awareness Month Kicks off on March 1, 2022https://practicaldermatology.com/news/cetaphil-sensitive-skin-awareness-month-kicks-off-on-march-1-2022/2461093/Cetaphil is extending Sensitive Skin Awareness Week to a month-long program. Cetaphil is debuting Sensitive Skin Awareness Month this March. In partnership with expert dermatologists and influencers – dubbed the Sensitive Skin Academy – Cetaphil 
- Vial Names Dr. Mark Lebwohl to Scientific Advisory Boardhttps://practicaldermatology.com/news/vial-names-dr-mark-lebwohl-to-scientific-advisory-board/2461091/The Vial Dermatology CRO has added Mark Lebwohl, MD, MPH to the Vial Scientific Advisory Board. Dr. Lebwohl will lend his expertise to the Vial CRO team and leading sponsors working to advance the Dermatology research field.<
- Positive Interim Data Seen with Sirnaomics Ltd’s STP705 in BCChttps://practicaldermatology.com/news/positive-interim-data-seen-with-sirnaomics-ltds-stp705-in-bcc/2461089/Interim data from a Phase 2 clinical trial of Sirnaomics Ltd’s STP705 shows a dose response with complete response, as well as improved or stable cosmetic result with no significant cutaneous skin reactions among patients with cutaneous basal cell carcinoma (BCC). The new data als